EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Expectations and clinical meaningfulness of randomized controlled trials

Ronald C Petersen, Paul S Aisen, J Scott Andrews, Alireza Atri, Brandy R Matthews, Dorene M Rentz, Eric R Siemers, Christopher J Weber, Maria C Carrillo

Alzheimer's & Dementia · 2023-06 · 19 (6) · 2730-2736

DOI: 10.1002/alz.12959 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 07.02.2023. Verfasst von Ronald C Petersen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 90-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement. Introducing treatment strategies early in the disease and assessing meaningful change over the course of an 18‐month clinical trial are critical to understanding the value to an effective intervention. With new clinical trial data expected soon on emerging therapeutics from several AD studies, the Alzheimer's Association convened a work group of experts to discuss key considerations for interpreting data from cognitive and functional measures and what is considered a clinically meaningful benefit or meaningful slowing of this fatal disease. Our expectations of outcomes from therapeutic interventions in AD may need to be modified.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionHumansMotivationRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Alzheimer diseaseMCIamyloidclinical meaningfulnessclinical trialcognitioncognitive impairmentdementiamild cognitive impairmenttau

Autor:innen und Institutionen

  • Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.
  • USC Alzheimer's Therapeutic Research Institute, San Diego, California, USA.
  • Takeda Pharmaceuticals, Cambridge, Massachusetts, USA.
  • Banner Sun Health Research Institute, Banner Health, Sun City, Arizona, USA.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.
  • Center for Alzheimer Research and Treatment, Brigham and Women's Hospital and Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Förderung

  • NIA NIH HHS

Zitieren

APA

Petersen, R. C., Aisen, P. S., Andrews, J. S., Atri, A., Matthews, B. R., Rentz, D. M., Siemers, E. R., Weber, C. J., & Carrillo, M. C. (2023). Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer's & Dementia, 19(6), 2730-2736. https://doi.org/10.1002/alz.12959

Vancouver

Petersen RC, Aisen PS, Andrews JS, Atri A, Matthews BR, Rentz DM, et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimer's & Dementia. 2023;19(6):2730-2736. doi:10.1002/alz.12959

BibTeX
@article{Petersen2023,
  author = {Petersen, Ronald C and Aisen, Paul S and Andrews, J Scott and Atri, Alireza and Matthews, Brandy R and Rentz, Dorene M and Siemers, Eric R and Weber, Christopher J and Carrillo, Maria C},
  title = {Expectations and clinical meaningfulness of randomized controlled trials},
  journal = {Alzheimer's & Dementia},
  year = {2023},
  volume = {19},
  number = {6},
  pages = {2730--2736},
  doi = {10.1002/alz.12959}
}
Kostenlos starten →